McKesson Co. (NYSE:MCK) Shares Sold by BDF Gestion

BDF Gestion reduced its position in McKesson Co. (NYSE:MCK) by 11.5% in the 4th quarter, HoldingsChannel.com reports. The firm owned 5,309 shares of the company’s stock after selling 691 shares during the quarter. BDF Gestion’s holdings in McKesson were worth $3,026,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently made changes to their positions in MCK. Synergy Asset Management LLC purchased a new stake in McKesson in the 4th quarter worth $32,000. MidAtlantic Capital Management Inc. purchased a new stake in McKesson in the 3rd quarter worth $29,000. Wolff Wiese Magana LLC increased its holdings in McKesson by 742.9% in the 3rd quarter. Wolff Wiese Magana LLC now owns 59 shares of the company’s stock worth $29,000 after acquiring an additional 52 shares in the last quarter. RPg Family Wealth Advisory LLC purchased a new stake in McKesson in the 3rd quarter worth $31,000. Finally, ORG Wealth Partners LLC purchased a new stake in McKesson in the 3rd quarter worth $40,000. 85.07% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on MCK shares. Robert W. Baird raised shares of McKesson from a “neutral” rating to an “outperform” rating and boosted their price target for the stock from $531.00 to $688.00 in a report on Thursday, November 7th. Baird R W raised shares of McKesson from a “hold” rating to a “strong-buy” rating in a report on Thursday, November 7th. StockNews.com raised shares of McKesson from a “hold” rating to a “buy” rating in a report on Wednesday, November 6th. Morgan Stanley upped their target price on shares of McKesson from $612.00 to $642.00 and gave the stock an “overweight” rating in a report on Tuesday, December 17th. Finally, Mizuho started coverage on shares of McKesson in a report on Wednesday, December 4th. They set a “neutral” rating and a $630.00 target price for the company. Two equities research analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $646.14.

Insider Buying and Selling

In other McKesson news, EVP Leann B. Smith sold 579 shares of the stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $572.79, for a total value of $331,645.41. Following the transaction, the executive vice president now directly owns 864 shares in the company, valued at $494,890.56. This represents a 40.12 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 0.11% of the company’s stock.

McKesson Price Performance

NYSE MCK opened at $603.79 on Thursday. The firm’s 50-day moving average is $592.16 and its two-hundred day moving average is $561.52. McKesson Co. has a 12 month low of $464.42 and a 12 month high of $637.51. The stock has a market capitalization of $76.64 billion, a P/E ratio of 31.27, a PEG ratio of 1.26 and a beta of 0.52.

McKesson (NYSE:MCK) last issued its quarterly earnings results on Wednesday, November 6th. The company reported $7.07 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.88 by $0.19. The business had revenue of $93.65 billion for the quarter, compared to analysts’ expectations of $89.33 billion. McKesson had a net margin of 0.77% and a negative return on equity of 207.50%. The business’s quarterly revenue was up 21.3% on a year-over-year basis. During the same quarter in the prior year, the company earned $6.23 earnings per share. As a group, analysts anticipate that McKesson Co. will post 32.73 EPS for the current year.

McKesson Company Profile

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.